Saranya Chumsri, MD, Mayo Clinic, Jacksonville, FL, provides an overview of an analysis of the Phase III North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) (NCT00005970) trial on the effects of intrinsic subtypes and 21-gene assay on the early and late recurrence risks in patients with early stage HER2+ breast cancer. The N9831 trial compared adjuvant doxorubicin and cyclophosphamide followed by either weekly paclitaxel; paclitaxel then trastuzumab; or paclitaxel plus trastuzumab followed by trastuzumab alone (arm C) in patients with HER2-positive breast cancer. A gene analysis was carried out using the Oncotype Dx assay and PAM50 assay. In patients with HER2-positive treated with adjuvant trastuzumab, with early risk of recurrence, ER, PR and estrogen axis were associated with improved outcomes. Invasion axis (MMP11, CTSL2), Oncotype Dx risk group, and basal subtype were also significantly associated with worse outcomes. None of the genes were observed to be associated with risk of late recurrence. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
